Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 8/20 | 0.49 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | VDR | P11473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945218 | 1.00 | ENPP2 (0.49) | ENPP2SERPINE1MGLLSIRT6VDR | |
| SCHEMBL945220 | 1.00 | ENPP2 (0.49) | ENPP2SERPINE1MGLLSIRT6VDR | |
| SCHEMBL12916396 | 0.94 | MAPT (0.46) | ENPP2SERPINE1MGLLSIRT6MAPT | |
| SCHEMBL12947498 | 0.91 | SIRT6 (0.43) | ENPP2SERPINE1MGLLSIRT6VDR | |
| SCHEMBL15354222 | 0.91 | SIRT6 (0.43) | ENPP2SERPINE1MGLLSIRT6VDR | |
| SCHEMBL15708312 | 0.89 | SIRT6 (0.42) | ENPP2SIRT6MAPTALDH1A1HTT | |
| SCHEMBL15724802 | 0.89 | SIRT6 (0.42) | ENPP2SIRT6MAPTALDH1A1HTT | |
| SCHEMBL15707960 | 0.87 | HRH3 (0.43) | ENPP2SERPINE1STAT3 | |
| SCHEMBL15707961 | 0.87 | HRH3 (0.43) | ENPP2SERPINE1STAT3 | |
| SCHEMBL12060056 | 0.87 | ENPP2 (0.55) | ENPP2SERPINE1MGLLSIRT6VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | ENPP2 196/4885SERPINE1 780/4885MGLL 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.